As we’ve been reporting, the media have a big role in fostering a public discussion of the cost of medicines and healthcare in general—the great unfinished businesss of health reform. For most of the Obamacare debate, the press acted as followers. This is a chance for reporters to take the lead, to move beyond the rhetoric of rationing the pols like to exploit to explanations of how to rationalize or improve the way we pay for drugs in this country—and, yes, how other counties control costs with, often, better outcomes.

Related content:

Covering the $1,000 pill

A drug offers better care for a disease that affects millions. How can it be ‘low value’?

If you'd like to get email from CJR writers and editors, add your email address to our newsletter roll and we'll be in touch.

 

Trudy Lieberman is a fellow at the Center for Advancing Health and a longtime contributing editor to the Columbia Journalism Review. She is the lead writer for The Second Opinion, CJR’s healthcare desk, which is part of our United States Project on the coverage of politics and policy. Follow her on Twitter @Trudy_Lieberman.